Harnessing the power of the Endocannabinoid System to create life-changing medicines
The mission of RS BioTherapeutics is to harness our strong and thorough understanding of the Endocannabinoid System in the research, development, and commercialization of forward-thinking interventions to address chronic and acute pulmonary inflammation-based diseases.
RS BioTherapeutic’s first investigational compound (RSBT-001) is a nebulized, semi-synthetic, cannabidiolic acid complex in development to address exacerbation and prevent progression of both acute and chronic pulmonary inflammation related to respiratory diseases including COPD, SARS-COV-2, Cystic Fibrosis, Asthma, Bronchitis, and Acute Respiratory Distress Syndrome. RSBT-001 is unique in that it is a polarity adaptive molecule exhibiting both hydrophilic and lipophilic properties, which leads to higher bioavailability. Our premise is that RSBT-001 provides therapeutic benefit through modulation of both the Interleukin response to inflammation and alveolar macrophages responsible for fibrotic changes within the lungs.
Our leadership team is comprised of industry leaders and specialists who are committed to the advancement of our vision and mission.
Meet the individuals on our advisory team.